IN8bio, Inc.
General ticker "INAB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $222.7M (TTM average)
IN8bio, Inc. does not follow the US Stock Market performance with the rate: -19.3%.
Estimated limits based on current volatility of 5.4%: low 1.76$, high 1.96$
Factors to consider:
- Total employees count: 18 (-41.9%) as of 2024
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Substantial doubt about continuing as a going concern, Operating losses, Product development risks, Public perception, Market competition
- Current price 65.6% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [5.30$, 18.33$]
- 2025-12-31 to 2026-12-31 estimated range: [4.55$, 14.97$]
Financial Metrics affecting the INAB estimates:
- Negative: with PPE of -13.1 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -5.93 <= 0.33
- Positive: Investing cash flow per share per price, % of -0.05 > -0.66
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Shareholder equity ratio, % of 69.13 > 63.39
- Negative: negative Industry operating cash flow (median)
Short-term INAB quotes
Long-term INAB plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $28.52MM | $30.34MM | $30.44MM |
| Operating Income | $-28.52MM | $-30.34MM | $-30.44MM |
| Non-Operating Income | $0.00MM | $0.33MM | $0.00MM |
| R&D Expense | $14.06MM | $16.83MM | $16.96MM |
| Income(Loss) | $-28.52MM | $-30.01MM | $-30.44MM |
| Profit(Loss)* | $-28.52MM | $-30.01MM | $-30.44MM |
| Stockholders Equity | $22.73MM | $24.94MM | $14.48MM |
| Assets | $33.04MM | $33.71MM | $20.94MM |
| Operating Cash Flow | $-24.12MM | $-23.34MM | $-24.15MM |
| Capital expenditure | $3.71MM | $0.60MM | $0.10MM |
| Investing Cash Flow | $-3.71MM | $-0.60MM | $-0.19MM |
| Financing Cash Flow | $8.99MM | $27.04MM | $14.18MM |
| Earnings Per Share** | $-1.36 | $-1.00 | $-0.57 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.